You just read:

Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 28, 2017, 01:00 ET